Roche Products Limited

Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, AL7 1TW
Telephone: +44 (0)1707 366 000
Fax: +44 (0)1707 338 297
WWW: http://www.rocheuk.com
Medical Information Direct Line: +44 (0)800 328 1629
Medical Information e-mail: medinfo.uk@roche.com
Customer Care direct line: +44 (0)800 731 5711
Medical Information Fax: +44 (0)1707 384555

Patient Information Leaflet last updated on the eMC: 22/12/2011
PIL Pegasys 180mcg solution for injection in a pre-filled syringe

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 04/07/2011 and displayed until 22/12/2011
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
Updated on 27/04/2011 and displayed until 04/07/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change of contra-indications
Updated on 10/11/2009 and displayed until 27/04/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 26/08/2009 and displayed until 10/11/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 12/12/2008 and displayed until 26/08/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 04/07/2008 and displayed until 12/12/2008
Reasons for adding or updating:
  • Change to side-effects
Updated on 08/04/2008 and displayed until 04/07/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 07/12/2007 and displayed until 08/04/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 19/07/2007 and displayed until 07/12/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 20/03/2007 and displayed until 19/07/2007
Reasons for adding or updating:
  • Change to date of revision
Updated on 17/01/2007 and displayed until 20/03/2007
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to date of revision
Updated on 05/12/2006 and displayed until 17/01/2007
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
Updated on 09/08/2006 and displayed until 05/12/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to date of revision
Updated on 13/06/2006 and displayed until 09/08/2006
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
  • Change to date of revision
Updated on 07/02/2006 and displayed until 13/06/2006
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
  • Change to date of revision
  • Change to side-effects
  • Change to storage instructions
  • Change to Further Information section
Updated on 16/03/2005 and displayed until 07/02/2006
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to side-effects
  • Change to Further Information section
  • Change to date of revision
Updated on 20/08/2003 and displayed until 16/03/2005
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   peginterferon alfa-2a